Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

Kenji Hashimoto

DOI: https://doi.org/10.1016/j.bcp.2020.113935

IF: 6.1

2020-07-01

Biochemical Pharmacology

Abstract:<p>Ketamine, an anesthetic developed in the early 1960s, is also a popular abused drug among young people at dance parties and raves and among spiritual seekers, because it produces schizophrenia-like symptoms and dissociation (i.e., out-of-body experience). Regarding mood disorders, ketamine exerts robust antidepressant actions in treatment-resistant patients with depression. Ketamine is a racemic mixture comprising equal parts of (<em>R</em>)-ketamine (or arketamine) and (<em>S</em>)-ketamine (or esketamine). The United States (US) Food and Drug Administration approved the J&amp;J (<em>S</em>)-ketamine nasal spray for treatment-resistant depression on March 5, 2019; the spray was then approved in Europe (December 19, 2019). Although (<em>R</em>)-ketamine has lower affinity for the <em>N</em>-methyl-<span class="small-caps">d</span>-aspartate receptor (NMDAR) vs. (<em>S</em>)-ketamine, (<em>R</em>)-ketamine has greater potency and longer-lasting antidepressant-like actions in animal models of depression. Importantly, (<em>R</em>)-ketamine has less detrimental side effects than does (<em>R,S</em>)-ketamine or (<em>S</em>)-ketamine in rodents, monkeys, and humans. A role for the brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB) receptor in the antidepressant effects of ketamine and its two enantiomers has been suggested. A recent RNA-sequencing analysis suggested that the transforming growth factor β1 (TGF-β1) plays a role in the antidepressant effects of (<em>R</em>)-ketamine. A recent pilot study demonstrated that (<em>R</em>)-ketamine had rapid-acting and sustained antidepressant effects in treatment-resistant patients with depression. In this article, the author reviews the mechanisms of the antidepressant actions of the enantiomers of ketamine and its metabolites, (<em>S</em>)-norketamine and (2<em>R</em>,6<em>R</em>)-hydroxynorketamine (HNK) and discusses the role of the brain–gut–microbiota axis and brain–spleen axis in stress-related psychiatric disorders, such as depression.</p>

pharmacology & pharmacy